The U.S. Food and Drug Administration announced Tuesday that Zyn nicotine pouches can be marketed as less harmful than cigarettes [1].

This decision provides a significant commercial advantage to Philip Morris International, the parent company of Swedish Match. By allowing a modified-risk claim, the FDA enables the company to target current smokers with scientific assertions regarding disease prevention, potentially shifting a large segment of the nicotine market.

The FDA concluded that Swedish Match provided sufficient scientific evidence to support the claim that switching to Zyn reduces the risk of several serious diseases [2]. According to an FDA spokesperson, using Zyn instead of cigarettes puts a user at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis [3].

Despite the approval of the marketing claim, the agency explicitly stated that Zyn is not safe [4]. The distinction is a critical regulatory boundary: the product is considered a lower-risk alternative for smokers, but it does not meet the criteria for being a safe product in its own right [4].

Approximately 20 versions of Zyn products are permitted to carry the reduced-risk claim [5]. This allows the company to apply the labeling across a wide variety of its flavor and strength offerings.

André Calantzopoulos, CEO of Philip Morris International, said the company is pleased that the FDA recognized the reduced-risk potential of Zyn [6]. The move is seen by industry analysts as a strategic pivot for the company's portfolio. Georgia Fearn said this decision gives Philip Morris a powerful new claim that could reshape the nicotine market [7].

The ruling follows a review process where the FDA determined that consumers would understand the specific modified-risk claims and that the evidence supporting them was accurate [2].

“Using Zyn instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”

This regulatory shift marks a transition in how the FDA manages harm reduction. By permitting a modified-risk claim, the agency is acknowledging that for an addicted population, a less harmful alternative is a viable public health tool, even if the alternative itself is not benign. This creates a legal pathway for tobacco companies to pivot toward non-combustible products while maintaining a scientific shield against claims of deceptive marketing.